



Rain Therapeutics to Present at Upcoming Investor Conferences

November 22, 2021

NEWARK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will participate in a fireside chat at the Piper Sandler 33rd Annual Healthcare Conference being held virtually November 29-December 2, 2021 and at the Evercore ISI 4th Annual Health CONx Virtual Conference being held virtually November 30-December 2, 2021.

Additional details can be found below:

Conference: Piper Sandler 33rd Annual Healthcare Conference

Date and Time: Prerecorded presentation will be available in advance beginning today, November 22, 2021, at 10:00 a.m. ET

Location: [Webcast Link](#) - or at the company's website ([click here](#))

Conference: Evercore ISI 4th Annual Health CONx Virtual Conference

Date: Thursday, December 2, 2021

Time: 3:00 p.m. ET

Location: [Webcast Link](#) - or at the company's website ([click here](#))

Replay of the presentations will be available by visiting the "[Events & Presentations](#)" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact

Jordyn Temperato

LifeSci Communications

+1.646.876.5196

jtemperato@lifescicomms.com

Investor Contact:

Bob Yedid

LifeSci Advisors

+1.646.597.6989

bob@lifesciadvisors.com



Source: Rain Therapeutics